Drug interactions
Anagrelide + Caplacizumab
Severity: Major
Anagrelide and Caplacizumab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Caplacizumab blocks von Willebrand factor-mediated platelet adhesion and anagrelide reduces platelet aggregation and count, so together they may increase the risk of serious bleeding. Bleeding is the main adverse effect of caplacizumab.
What this interaction means in plain words
Anagrelide and Caplacizumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Anagrelide belongs to Cardiovascular; Caplacizumab belongs to Cardiovascular.
Why it happens
Additive impairment of primary hemostasis through different antiplatelet pathways.
What to do
Avoid combined use where possible; if anagrelide must be continued, monitor closely for bleeding and check platelet count and hemoglobin. Hold therapy as advised in caplacizumab labeling if significant bleeding occurs.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Anagrelide and Caplacizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Anagrelide
- Anagrelide + Panobinostat Contraindicated
- Anagrelide + Pimozide Contraindicated
- Anagrelide + Thioridazine Contraindicated
- Anagrelide + Vandetanib Contraindicated
- Abrocitinib + Anagrelide Major
- Alfuzosin + Anagrelide Major
Other interactions of Caplacizumab
Frequently asked questions
Can I take Anagrelide with Caplacizumab?
MediHelp rates the interaction as major. Anagrelide and Caplacizumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Caplacizumab blocks von Willebrand factor-mediated platelet adhesion and anagrelide reduces platelet aggregation and count, so together they may increase the risk of serious bleeding. Bleeding is the main adverse effect of caplacizumab.
How serious is the interaction between Anagrelide and Caplacizumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combined use where possible; if anagrelide must be continued, monitor closely for bleeding and check platelet count and hemoglobin. Hold therapy as advised in caplacizumab labeling if significant bleeding occurs.
What other medicines interact with Anagrelide?
MediHelp also lists interactions of Anagrelide with, for example, Panobinostat, Pimozide, Thioridazine. The full list is on the Anagrelide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
